Answer
Dupilumab (Dupixent) is indicated for eosinophilic oesophagitis in adults, adolescents and children aged 1 year and older, weighing at least 15 kg, whose disease is inadequately controlled by conventional medicinal therapy, who cannot tolerate it, or who are not candidates for it.
Sources for this answer
- Dupixent 300 mg solution for injection in pre-filled syringeSANOFI · emc · SmPC §4.1 Therapeutic Indications · Version 27Document updated
Sources checked